We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Walsh Aviation Limited has plans to create a low altitude airborne data acquisition method using the latest in Gyroplane technology. They have a 20-20-20 target to be able to fly at an altitude of 20 meters above the vegetation canopy, with a speed of 20 knots and to provide the service profitably at £20 per line kilometre.   
days to go: Expired investment: £61,000
Please watch the video for more information
days to go: Expired investment: £328,193
Advanced Blast & Ballistic Systems (ABBS) is a company that has developed globally patented systems to counteract the forces an armoured vehicle sustains when a mine or Improvised Explosive Device (IED) explodes under it. ABBS asserts that mines and IEDs accounted for over 80% of UK and US army casualties in Iraq & Afghanistan. ABBS aims to change this and become a major contender in the $20 billion armoured vehicle protection market. The company has received over £2 million in revenue to date from Research and Development (R&D) grants in the UK, as well as, sold its products to the US Army and Israel with profits worth £145,000 in 2018 and £560,000 in 2019 respectively. ABBS is in potential talks with Pakistan, India, and the Far East. It will use 35% of the investment for the development of its Zero-Zero Safety System for eVTOL aircraft, 10% for patent protection, 25% towards investment in existing R&D/production facility, and 30% towards R&D/Marketing staff.
days to go: Expired investment: £154,810
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go: Expired investment: Withheld
Active Needle is a medical device company that aims to prevent the problem of needle placement errors in ultrasound-guided needle interventional procedures. The technology allows for precision needle targeting.
days to go: Expired investment: £147,514
addvantage offers patented, fuel-saving technology that retrofits to heavy-duty trucks, thereby improving fuel economy, reducing harmful emissions and saving money for diesel-driven trucking fleets. Addressing two key challenges of the trucking industries--low margins and the need to reduce emissions--addvantage has a proven track record in the UK and is now launching in the US, where more than 4 million heavy duty class 8 trucks are operational. With diesel making up 40% of the trucking fleet costs in the US, the company provides compelling economics and environmental arguments for these fleets. addvantage is an exciting opportunity for investors looking for tax efficient, high growth opportunity with green credentials.
days to go: Expired investment: £394,155
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
Arc's aim is to become the market leader in electrical recreational vehicles by using licensed battery automotive technology as the base. The company was born out of Jaguar Land Rover’s White Space. Since its pre-launch, the ‘Vector’ has attracted global interest with over 590 news articles covering its release across 55 countries. Arc also witnessed over 130 sales inquiries in relation to the limited 399 units which it is planning to produce. The company is on a mission of creating vehicles that challenge the environment while protecting it.
days to go: Expired investment: £1,067,420
Arcis Biotechnology provide nucleic acid sample preparation solutions. They have made the process of obtaining genetic material from biological samples less time consuming so it can be done in less than 3 minutes.
days to go: Expired investment: £1,146,318
A ride-hailing service offering customers the ability to select a driver of their choice based on price, distance, or rating. Arrive aims to solve common issues such as longer-than-expected ETAs and unexpected price increases by showing fixed information of the journey prior to booking. The service benefits drivers with high ratings, as they will have increased demand for their services, which means they will be able to monetise far greater. In-turn, those with lower ratings will become more motivated to improve their service. Arrive's AdTech platform allows the company to collaborate with businesses and offer affiliation marketing and promotional deals. Customers travelling to particular restaurants, bars, or clubs can receive specialised treatment and discounts. Arrive is currently in beta, but has over 1,500 drivers signed-up to the service and their app has received more than 15,000 downloads.
days to go: Expired investment: £56,170
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph